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ABSTRACT OF DISSERTATION

THE ROLE OF PHLPP IN PANCREATIC CANCER
Medicine has come a long way in recent years with reliable treatments for
many cancers. Pancreatic ductal adenocarcinoma (PDAC) has very few
treatment options available. PDAC has a dismal 5 year survival rate of 4% and a
median survival span of 6 months from point of diagnosis; with a high rate of
chemotherapy and radiation resistance. A better understanding of the molecular
events leading to cancer progression is needed in order to improve the treatment
and prognosis of PDAC patients. We begin to elucidate the functional importance
of PHLPP on suppressing progression and metastasis of PDAC. PHLPP belongs
to a novel family of Ser/Thr protein phosphatases. Our previously published
studies have demonstrated that PHLPP plays a tumor suppressor role in colon
cancer by negatively regulating Akt and inhibiting cell proliferation. To determine
the effect of PHLPP on cell migration and invasion, stable cells were generated
to knock down or overexpress PHLPP in PDAC cells. The ability of cells to
migrate and invade was examined using Transwell assays. We found that
increased PHLPP expression significantly reduced the rate of migration and
invasion in PDAC cells whereas knockdown of PHLPP had the opposite effect.
To begin to elucidate the molecular mechanism underlying PHLPP-mediated
inhibition of migration and invasion in PDAC cells, we discovered that the
expression level of β4 Integrin was decreased in PHLPP overexpressing cells
and increased in PHLPP knockdown cells. The increased expression of β4
Integrin has been shown to promote PDAC development and metastasis,
although the mechanism leading to β4 Integrin upregulation is less clear.
Interestingly, we found that the expression of β4 Integrin was highly sensitive to
PI3K/Akt/mTOR activity in cells in which inhibition of PI3K/Akt/mTOR signaling
significantly decreased the expression of β4 Integrin. Moreover, the quantitative
real-time RT-PCR analysis revealed that the mRNA expression of β4 Integrin
was not altered by changes in PHLPP expression or PI3K/Akt/mTOR activity,

thus suggesting a post-transcriptional mechanism. Taken together, these results
identify a tumor suppressor role of PHLPP in PDAC. Mechanistically, PHLPP
suppresses PDAC cell migration and invasion by negatively controlling β4
Integrin expression through its ability to inhibit PI3K/Akt/mTOR signaling.
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Chapter 1. Introduction
The Pancreas
The pancreas is a unique organ that is physically situated behind the
stomach.

The word pancreas itself is derived from the Greek roots “pan”

meaning “all” and “creas” translated to “flesh” [1]. It is considered part of both the
exocrine and the endocrine system.

As a glandular organ the pancreas is

responsible for actions within the digestive system as well as regulating sugar
homeostasis in the blood.
The organ itself is around 15-25 cm in length and weighs approximately
70-150 grams [1, 2]. The head of the organ is “nestled” into the duodenum while
the body lays behind the stomach and the tail of the pancreas is near the spleen.
The main pancreatic duct runs the length of the pancreas, combines with the
common bile duct, and empties its contents into the duodenum through the
Ampulla of Vater (Figure 1.1) [2].

Histology of the pancreas
The pancreas as explained earlier is a unique organ that is both part of the
exocrine and endocrine system. In order to achieve this multi-functional and
duality role for the pancreas the specialized cells of the pancreas must be
arranged in such a way that it allows for separation of function and
compartmentalization. Anatomy of both the exocrine and the endocrine portion
of the pancreas will be discussed below.

1

2

Figure 1.1. Anatomy of the pancreas
The head of the pancreas is nestled into the duodenum while the tail extends
towards the spleen (adapted from [2]).
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Exocrine Structure
The exocrine portion of the pancreas is responsible for aiding in food
digestion.

In order for the pancreas to complete this task it must release

digestive enzymes into the duodenum. Without the exocrine function then
individuals would find themselves in a state of malnutrition [2, 3]. Not only does
the pancreas secrete digestive enzymes, but also releases ions and water into
the duodenum as well. This is important for a few major reasons. The water
helps transport the enzymes as well as the food on into the digestive tract and
the ions help to neutralize the pH of the gastric chyme. The alkalinity of the
pancreatic exocrine juices is due to the high concentration (up to 140 mM) of
NaHCO3 within the secretion. If the gastric chyme was allowed to maintain an
acidic pH then the digestive enzymes would lose activity [3].
The exocrine pancreas consists of the acinus and the draining ducts. The
acinar cells drain into the acinus ducts which lead to the interlobular ducts. The
interlobular ducts then make way to the main pancreatic ductal system. The
acini can be of multiple forms, including spherical, tubular, or an in between form.
They are tasked with synthesizing, storing, and secreting digestive enzymes.
The basolateral side houses receptors for both hormones and neurotransmitters
whereas the apical side contains the zymogen granules with the digestive
enzymes inside of them [3].
The centroacinar cell is a unique cell within the pancreas in that it acts as
a progenitor for different types of cells [3, 4]. Recently, a new cell type called the
pancreatic stellate cell was discovered in the pancreas. They are star-shaped
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cells believed to be responsible for laying down the basement membrane. These
stellate cells are currently being investigated for their role in pancreatic cancer
development [3, 5]. Then we have the ductal epithelial cells, which are
responsible for the formation of ductal passages within the pancreas as well as
where the most common form of pancreatic cancer arises from [3].
The digestive enzymes found within the pancreas are actually capable of
digesting the very organ that produces them.

Therefore, in order to prevent

these harmful events mechanisms such as storage in acidic granules have
evolved [3, 6]. Another such prevention is the synthesis and storage of some of
these enzymes as precursors. They are found as proenzymes in the pancreas
but quickly activate within the duodenum. This activation occurs when trypsin is
activated through an enzyme called enterokinase, which removes the N-terminal
hexapeptide fragment on trypsin. Trypsin is then free to exert its activity onto the
proenzymes. An inhibitor of trypsin called PSTI (Pancreatic Secretory Trypsin
Inhibitor) is also synthesized in the secretory pathway of the digestive enzymes
as well as the zymogen granules [3, 6].
Amyase is an enzyme that is secreted in both the pancreas and the
salivary glands.

However, the salivary gland secreted form has a different

molecular weight and electrophoretic mobility.

This may be attributed to the

difference in its carbohydrate content. For both isoforms the enzymatic activity
remains the same in that they digest both starch and glycogen. The optimum pH
for activity is neutral pH but you will find it active in the stomach acid [3, 7].

5

Another active enzyme called lipase is primarily secreted by the pancreas.
It is capable of hydrolyzing a triglyceride molecule to two fatty acid molecules
from carbons 1 and 3. This hydrolyzing reaction also leads to a monoglyceride
released with a fatty acid esterified to a glycerol at carbon 2. The interesting part
is how the lipase is able to perform its reaction in a water environment when oil
and water do not mix.

The function of lipase is facilitated by bile acid and

colipase. They aid in the binding of lipase to the oil/water interface of triglyceride
droplets, where lipase exerts its activity [3, 8]. In addition, phospholipases
hydrolyze fatty acid ester linkage at carbon 2 of phosphatidylcholine [3, 8].
Proteases are enzymes that aide in the breakdown of proteins from
consumed food. There are two major types of proteases: endopeptidases and
exopeptidases. Regardless of type of proteases, all are stored as the proenzyme
form inside of the zymogen granules. This keeps them inactive until they are
deposited in the duodenum where they are activated by trypsin. Interesting
enough trypsin is an example of endopeptidase as well as chymotrypsin.
Endopeptidases cleave peptide bonds of proteins internally at specific sites.
Exopeptidases however cleave 1 amino acid at a time either from the NH 2 or
COOH terminal ends of the protein. Further digestion of oligopeptides and free
amino acids occur through the brush-border enzymes. From there they may be
transported across the transluminal surface of the small intestine by Na +-H+
coupled transporters [3, 9].
Some of the inorganic compounds found in the pancreatic secretions into
the duodenum aren’t just water, but contains many ions: sodium, potassium,
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chloride, and bicarbonate.

They are just as important in the function of the

exocrine pancreas as the enzymes themselves. They provide the flow of the
enzymes from the acinus to the duodenum as well as allowing for the change of
the pH of the gastric chyme from acidic to neutral [3, 10, 11].
In summary, the exocrine pancreas is a beautiful conglomerate of
cooperative enzymes and compounds that work in cohesive unity to provide
nourishment for a large and extremely diverse organism.

Endocrine Structure
The endocrine system is dispersed throughout the exocrine system and
tissue within the pancreas. These hormone secreting cells are grouped together
in little areas referred to as islets, which can be translated to as a small island or
in anatomy as a distinct portion of tissue surrounded by entirely different tissue.
Langerhans believed in 1869 that he was seeing intrapancreatic lymph nodes
[12]. This was later disproven however not only are hormone secreting cells
present but so are nerve cells as well as the area being highly vascularized [13].
The islets of Langerhans is the distinct tissue that house the hormone
secreting cells of the endocrine system within the pancreas. There are around a
million islets found in the average pancreas of a healthy adult [13, 14]. Each islet
measuring around 0.2 mm in diameter is surrounded by a capsule made of
fibrous connective tissue. There are five major cell types found in the islets:
alpha, beta, delta, PP, and epsilon [13-15]. The alpha and beta cells in the islet of
Langerhans play the principle role in regulating blood glucose levels by the
7

coordinated secretion of glucagon and insulin, respectively. The alpha and beta
cells work in opposition to each other. The activity of alpha cells is stimulated
during times of hypoglycaemic conditions. Alpha cells secrete glucagon which
exerts

a

catabolic

effect

through

activation

of

glycogenolysis

and

gluconeogenesis within the liver. Compared to the vast knowledge of beta cell
structure and function little is known about the alpha cells.

This lack of

knowledge is primarily due to the low concentration of alpha cells within the islets
and the lack of techniques available for isolation and characterization. What is
known is that at low levels of glucose ion channels generate action potentials
through Na+ and Ca2+. This electrical activity triggers the release of glucagon.
When the concentration of glucose rises these events are inhibited. There are
other mechanisms that glucagon release could be controlled by such as through
fatty acid exposure but very little is known about these different regulations [13,
15, 16].
The beta cells are the most studied and well-characterized cells that
reside in the islet. They typically make up the majority of the cell population as
well. These hormone producing cells secrete insulin. In contrast to glucagon,
insulin activates glycogenesis or the production of glycogen within the liver.
[Kelly] [Eleyat] [Korc] In beta cells the ATP-sensitive K+ ion channels are open
while the voltage gated Ca2+ ion channels are closed during resting conditions.
In response to an increase in glucose concentration, glucose is diffused across
the membrane into the cell through GLUT2 transporters via facilitated diffusion.
Glucose undergoes glucose metabolism leads to increased production of ATP.
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The ATP/ADP ratio changes and as ATP concentration increases it closes the K +
ion channels inhibiting the transport of K+ outside of the cell. As the potassium
levels rise inside the cell the voltage gated Ca2+ channels are activated allowing
the calcium ions to cross the cell membrane into the cell [13, 15, 17]. Once inside
they bind to their respective receptors allowing the insulin containing vesicles
within the cell to bind to the inside of the cell membrane allowing for the release
of the insulin through exocytosis [13, 15, 18] (Figure 1.2).
The delta cells found in the islet of Langerhans in the pancreas produce a
hormone called somatostatin. One interesting note about somatostatin is that it
inhibits the function of both the alpha cells and the beta cells. [[19] Delta cells
are thought to only affect the adjacent alpha and beta cells. [20] It is believed
that somatostatin is either diffused through the interstitium or transported via the
microvasculature of the islet itself[21]

PP cells are also referred to as the

Gamma cells and make up an even less population of the islets than the delta
cells.

PP cells secrete a protein called pancreatic polypeptide or PP.

The

highest concentration of PP can be found towards the head of the pancreas. [22]
PP is believed to regulate appetite and food intake. It has been found to be of
lower concentrations after eating but significantly expressed in anorexia nervosa
patients. [23]The least abundant cell in the islets is known as the epsilon cell.
Epsilon cells produce a hormone called ghrelin, which inhibits the release of
insulin from beta cells within the islets. It is considered a local regulator of insulin
just like PP produced by the gamma cells. Ghrelin is being considered as a
possible target for diabetes treatment. [24, 25]
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The information presented above is a brief summary of a simplistic
overview of the function of the pancreas and it is easy to see how pancreatic
cancer is so very catastrophic to the individual.

10
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Figure 1.2. Insulin secretion in beta cells of the pancreas.
While in the normal resting state (low glucose) the K+ channel is open allowing
for the K+ ions to cross the membrane and travel to outside the cell. As glucose
concentration increases it is transported through facilitated diffusion by the
GLUT2 transporter into the beta cell of the pancreas. From there it goes through
glucose metabolism which gives the final product of ATP. As ATP concentration
increases it binds to the K+ ion channels causing them to close. Eventually this
membrane depolarization allows for the Ca2+ channels to open which gives an
influx of Ca2+ ions. This leads to the vesicles containing insulin to bind to the cell
membrane releasing insulin through exocytosis (adapted from [18]).

12

Risk Factors and Pancreatic cancer
Before we get to the heart of pancreatic cancer we need to look at some
risk factors. Three major risk factors have the capacity to affect a large majority
of the American population in various ways: smoking, diabetes, and pancreatitis.
Looking at the 2013 statistics for smoking in the United States roughly 18
out of 100 adults smoked which translates to 42.1 million adults who smoke.
This preventable epidemic kills around 480,000 Americans each year [26]. Since
the act of smoking doubles the risk of pancreatic cancer and around 20-25% of
all pancreatic cancers are caused by smoking, it is imperative that the link
between the two be understood [27]. Other studies have demonstrated that
smoking increases the expression of oncogenes in specific tissues, such as the
lung. This includes mutation in the KRAS gene. As we will see later KRAS is
found activated in 90% of all pancreatic cancers. Understanding the mechanism
on activation of KRAS is also of the utmost importance and it may be linked to
smoking [28]. However, it should be noted that the majority of studies linking
smoking to pancreatic cancer has epidemiological [27, 29]. There has been a few
interesting studies to note that in pancreatic cancer patients who were smokers
not only did they harbor more mutations but also a larger variety of point
mutations [29].
Diabetes mellitus or diabetes is a collection of disorders that give
enhanced blood sugar levels for a sustained time period [30]. There are three
major types of diabetes: Type I, Type II, and gestational. Type I diabetes is due
to beta cell loss in the pancreas, typically an immune destruction [31]. Type II
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diabetes is the inability of cells to respond to insulin [32]. Gestational diabetes is
an interesting case where pregnant women with no previous history of diabetes
develop high blood sugar [33]. Through a large meta analysis it was discovered
that 75% of pancreatic cancer patients also carried diabetes mellitus [34]. The
risk factors for developing pancreatic cancer through diabetes are most likely
through prolonged insulin exposure. Insulin can regulate cell proliferation as a
growth hormone. While in diabetes the cells may become resistant to insulin as
far as being able to reduce glucose in the blood, the other effects of insulin may
still be prevalent. Another action of insulin is to decrease the insulin-like growth
factor binding protein thereby increasing insulin-like growth factor or IGF. IGF is
an even stronger oncogene than insulin [35]. It is quite easy to understand how
preventing diabetes or treating it successfully could have an impact on pancreatic
cancer statistics.
Pancreatitis is a disorder characterized by inflammation of the pancreatic
organ.

One interesting aspect of the relationship between pancreatitis and

pancreatic cancer is the genetic mutations found in pancreatitis is also found in
pancreatic cancer [36, 37]. Morphological and functional changes within the
pancreas can be found in chronic pancreatitis patients. There are some common
cytokines that are found in both. These include IL-6, TNF-alpha, IL-8, PDGF,
and TGF-beta [38]. Another interesting finding is that macrophages which are
regulators of inflammation and secrete pro-inflammatory cytokines are found
throughout histological samples of pancreatic cancer as well as pancreatitis [39].
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Repeated tissue damage through inflammatory reactions during chronic
pancreatitis leads to pancreatic cancer formation [39].

Pancreatic Intraepithelial Neoplasia (PanIN)
Pancreatic Intraepithelial Neoplasia or commonly referred to as PanIN is
the step-wise characterization of pancreatic lesions leading into carcinoma.
PanINs are found to be more common in pancreata histological sections of
pancreatic cancer patients than in chronic pancreatitis; however, they are more
prevalent in chronic pancreatitis patients than typical patients [40]. It is important
to note that there are two other types of lesions found in pancreatic cancer
patients; however, they are significantly less profound and the PanIN lesions are
the most common. The other two lesions are called mucinous cystic neoplasm
[41] and intraductal papillary mucinous neoplasm (IPMN). Due to the prevalence
of PanIN lesions we will focus on those [40].
PanIN development at each stage has been extensively studied. Common
gene mutations as well as morphological phenotypical changes have
characterized and associated with each stage (Figure 1.3) [42, 43]. There are 4
known stages of PanIN: PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3. PanIN-1A
and PanIN-1B are considered low-grade lesions that are flat (PanIN-1A) or
papillary (PanIN-1B) in nature with typical nuclear phenotypes. PanIN-1A is
considered to have tall columnar cells and can be indistinguishable from nonneoplastic lesions. PanIN-1B is basically indistinguishable from PanIN-1A except
that it is papillary in nature.

PanIN-2 lesions are much more complex with
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atypical nuclear characteristics including loss of nuclear polarity, nuclear
crowding,

pleomorphism,

nuclear

pseudostratification,

and

nuclear

hyperchromasia. PanIN-3 lesions are considered carcinoma-in-situ with loss of
polarity, nuclear atypical, and mitosis. However, PanIN-3 lesions are still found at
the basement membrane.
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Figure 1.3. PanIN development.
There are 4 stages of PanIN: PanIN-1A, PanIN-1B, PanIN-2, and PanIN-3. Each
PanIN stage is characterized by known mutations within the pancreatic ductal
cells as well as phenotypic changes. This figure is adapted from Koorstra et al.
[42].
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Many times you can see budding off of small cluster cells, some necrosis,
and goblet cell irregularities [42-45]. From this point carcinoma develops where
there is invasion and loss of basement membrane localization. Activation of
oncogenes such as KRAS and inactivation of tumor suppressors such as SMAD4
and CDKN2A/INK4A allow tumors to progress from PanIN to carcinoma [46, 47].
There have been some recently discovered morphological evidence that
gives detail as to how these lesions can cause further damage to the pancreas.
Recently, PanIN lesions have been noted to have lobulocentric atrophy. This
type of atrophy would be able to decrease acinar cell flow of the secretions
raising the possibility of a localized inflammatory reaction. Interesting to note that
KRAS mutations were found in these samples [48].
As will be further explained below there have been characterization of the
genetic changes that occur during PanIN development. Although a specific order
has not been determined it does seem that some mutations occur before others,
such as the activating KRAS mutation is set before the p53 mutation [40].
Telomere shortening was recently discovered to be present in PanIN-1 lesions.
This could possibly be used as a histological technique to identify patients with
chronic pancreatitis who are at risk of developing pancreatic cancer [40].
As we have seen genetic alterations that are found in pancreatitis, PanIN
development and pancreatic cancer protein expression profiles are significantly
similar between both PanIN lesions and pancreatic cancer. These changes of
protein expression range from enhanced expression of survivin and adhesion
molecules. Mucins are another protein that is expressed in both PanIN type
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lesions and pancreatic cancer but not other types of pancreata lesions. Mucins
can be used to distinguish between the different types of lesions and signal to the
treating physician that the patient has a heightened possibility of developing
pancreatic cancer [40, 47, 49].

Genetic alterations in pancreatic cancer
There are many risk factors currently known that increase the risk of
developing PDAC and this includes is but not limited to age, smoking, obesity,
diabetes, and pancreatitis [50]. An increased risk for developing PDAC can also
be seen in familial clustering indicating that hereditary gene mutations contribute
to PDAC development [51, 52]. The Cancer Genome Atlas project has identified
a number of genetic alterations in human pancreatic cancer. Table 1.1 shows the
most common mutations that are found in pancreatic cancer. The functional
contribution of these genetic mutations as well as other genetic alterations in
pancreatic cancer are discussed in more details below and followed by a
separate section on KRAS.
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Gene

Chromosome

Percentage of

Type of

Location

cancers with a

Mutation

mutation
KRAS

12p13

>90%

Gain

of

Function
P16INK4/CDKN2/MTSI 9p21

80%

Loss

of

Function
TP53

17p13

50%-75%

Loss

of

Function
DPC4/SMAD4

18q21

~50%

Loss
Function
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Table 1.1. Common genetic mutations found in pancreatic cancer.
Pancreatic cancer carries some unique common genetic mutations. These
interesting mutations may present a variable chemotherapy treatment target that
is unique for pancreatic cancer.
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P16INK4/CDKN2/MTSI genetic variations in pancreatic cancer
Cyclins, have no intrinsic activity, bind to cyclin-dependent kinases or
CDKs and target them to subcellular locations as well as help activate them.
When bound with their respective CDKs the complex is called maturationpromoting factor [53]. CDKs are serine threonine kinases that regulate the cell
cycle [54]. Taking it from there inhibitors of CDKs are called cyclin-dependent
kinase inhibitor proteins or CDKIs or CKIs.

There are two families of CKIs:

Inhibitors of CDK4 (INK4) and the KIP family. The INK4 family of CKIs house 4
members which include p16 (INK4a), p15 (INK4b), p18 (INK4c), p19 (INK4d).
These 4 members are considered tumor suppressors [55]. The gene for p16INK4
is referred to as CDKN2. At another point the protein was also called multiple
tumor suppressor gene 1 [41].
INK4a, found on chromosome 9, can undergo a homozygous deletion, an
intragenic mutation, and hypermethylation of the promoter [42, 49, 56-58]. The
INK4a gene arrests the cell between the G1-S phase through binding to CDK4/6
and inhibiting its action. CDK4/6 binds to cyclin D and becomes an active
complex

that

phosphorylates

retinoblastoma

protein

(pRB).

Once

phosphorylated, pRB is able to disassociate from the transcription factor E2F1.
When E2F1 is freed from pRB it is able to enter into the nucleus and promote
transcription of genes that promote cell cycle progression. [59] Therefore,
inactivation of p16 leads to activation of CDK4 and CDK6 and subsequent cell
cycle progression without the proper checks and balances [55]. It seems that the
other INK4 proteins (INK4b,c,d) are not involved in the etiology of cancer
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according to current research [55]. Homozygous deletions of INK4a have been
found in lymphomas and sarcomas as well as childhood leukemias [60, 61].
Hypermethylation of the promoter of INK4a have also been seen in cancers as
well [62].
Mutation of p16 is found in virtually all pancreatic cancers, but also seen
in the PanINs: 30% PanIN-1A and 1B, 50% PanIN-2, and 71% in PanIN-3 [42,
63].

It was recently shown that KRAS activation and loss of INK4a locus

combined can give rise to ductal adenocarcinoma through progression of PanINs
[64]. They are considered coordinating pathways that promote carcinogensis.
The coordinating link may be through the relationship of INK4a and constitutively
active KRASG12V. The KRASG12V is most likely the initiating mutation for pancreatic
cancer development; however, subsequent deletion of INK4a would confer
sustained activity of KRASV12 without interference of any attenuating factors
[65]. Attri et al found that around 80% of pancreatic tumors had some sort of
INK4a inactivation change.

These changes include the intragenic mutation,

hypermethylation and homozygous deletion [66]. Future investigations should
revolve around INK4a and its possible activity and influence on KRAS as well as
how the different types of INK4a mutations could affect the outcomes of
pancreatic cancer. Samples from pancreatitis patients could be evaluated for
INK4a mutations. If changes in INK4a were present it would give validation that
these patients need to be carefully followed for development of pancreatic
carcinoma.
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TP53 genetic variations in pancreatic cancer
The tumor suppressor p53 (encoded by the TP53 gene) has many roles
within the cell, but the major role that is exploited in cancer is its role in the arrest
of the cell cycle at the G1/S phase. Through binding of p53 to a specific p53
binding site on the promoter of gadd45, it is able to induce transcription. Once
GADD45 is transcribed it can interact with PCNA to initiate nucleotide excision
repair.[67] There are also some other mechanisms in which p53 activates DNA
repair, but those are quite intensive and not necessary for understanding the
general role of p53. Apoptosis control is another area of active research
concerning p53 [68].
One of the most common genetic mutations found in cancer is actually in
p53 [69]. Mutations of p53 at an intragenic site coupled with loss of second allele
occurs in greater than 50% of pancreatic cancers [49]. The typical mutation is
within the DNA-binding region that contacts the DNA. These type of mutations
result in loss of ability for p53 to bind to the DNA and affect transcription of target
genes [70]. While it is true that mutant p53 is a loss of function events, there is a
caveat that these mutations may cause p53 to act like a dominant negative and
exert a type of gain of function. This was shown when sustained expression of
p53 lead to increase activation of PDGFRβ (Platelet Derived Groth Factor
Receptor beta) [71]. The p53 loss of function mutation tends to occur during
PanIN-3, and again correlates it with a late genetic event [72, 73]. It is interesting
to note that most of the commonly used pancreatic cell lines all carry p53
mutations [74]. The focus of studying p53 mutations in pancreatic cancer is to
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uncover the possibility of new or adjuvant treatments.

While these new

treatments would most likely require early detection that is why investigation into
PanIN development from associated with risk factors would provide so useful.
DPC4/SMAD4 genetic variations in pancreatic cancer
SMAD4 a tumor suppressor and downstream signaling event of the
transforming growth factor β (TGF-β) family, is found mutated in ~50% of
pancreatic cancers and is a late genetic event like p53 [49, 74]. SMAD4 is
involved as a co-SMAD that binds to other members of the SMAD family like
SMAD2. Together the complex is able to bind to DNA sequences and affect
transcription of targeted genes.

The most common mutation is homozygous

deletion, loss of an allele coupled with intragenic mutation. SMAD4 accumulates
in the nucleus after TGFβ is stimulated. SMAD4 functions to check cell cycle
arrest, and to regulate apoptosis [42]. Patients who had resective surgery did
significantly better if their tumors expressed wild type SMAD4 [75]. The 5 year
survival advantage of patients who expressed wild type SMAD4 was determined
to be approximately 20% whereas only 13% survived to 5 years without SMAD4
expression. Although it is currently not known which of SMAD4s activities are
biologically advantageous what is known that patients have a poorer outcome
without SMAD4 expression warranting further studies in its activities [75].
Genetic alterations in pancreatic cancer could be used as a histological
reference in patients who are at risk for developing PDAC. These high risk
patients would include pancreatitis patients, diabetic patients, and smokers.
Going forward in this study we decided to look a little deeper into oncogenic
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aberrations in pancreatic cancer, specifically events that lead to changes in the
PI3K/Akt and Raf/MEK/ERK pathways.
EGFR and HER2/neu amplification in pancreatic cancer
The Epidermal Growth Factor Receptor (EGFR) and Her2/neu (ERBB2)
are transmembrane receptors belonging to the ERBB receptor tyrosine kinase
family [76]. EGFR and Her2 can function as heterodimers in cells. The ligands for
EGFR include EGF, TGF-β, amphiregulin, and epiregulin [77]. After ligand
binding, EGFR activates two well known oncogenic pathways the PI3K/Akt
pathway and

the

Raf/MEK/ERK pathway.

EGFR-mediated signaling

is

upregulated in many malignancies. This upregulation can come from gene
amplification or upregulation of EGFRs respective ligands [78]. An activating
mutation in the kinase domain leads to unchecked activity of EGFR in the
absence of ligands [79]. The expression of EGFR in the pancreas is typically
limited to the ductal cells or the Islet of Langerhans. Overexpression of EGFR is
found in 40% to 70% of pancreatic cancers and HER2 overexpression in a
smaller subset of cases [80]. Association of EGFR in pancreatic cancer is found
in high-grade tumors especially. Therapeutic strategies aimed at targeting both
EGFR and Her2 receptors are being developed to treat pancreatic cancer [8183]. These therapeutic strategies may prove to be non useful as greater than
90% of all advanced pancreatic cancer carries the activating KRAS mutation.
KRAS works downstream of EGFR and other receptor tyrosine kinases.
Inhibiting EGFR would have little effect on prognosis of advanced patients;
however, there is always hope as adjuvant treatment [64, 82].
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Hedgehog signaling in pancreatic cancer
It was recently discovered that in approximately 75% of PDAC tumors
Hedgehog (Hh) signaling is dysregulated, and specifically there is aberrant Hh
ligand expression [84]. Hh signaling is found in embryonic development where
different parts of the embryo have different expression of Hh ligands allowing for
polarity to occur. There are three secreted ligands: sonic hedgehog (SHH),
Indian hedgehog (IHH), and Desert Hedgehog (DHH). These Hh ligands signal
through binding to a receptor called Patched or (PTC); however, without Hh
ligands PTC binds to Smoothened or SMO and represses its activity. When Hh
binds to PTC the repression of SMO is released allowing for the Gli nuclear
family of transcription factors to accumulate. Gli transcription factors activate
factors that allow for proliferation such as cyclin D and evasion of apoptosis such
as BCL2 [44, 85]. Activation of Hh signaling promotes PDAC via two different
mechanisms: i) Hh ligands are over-expressed in the tumor microenvironment,
which leads to hyperactivation of Hh signaling in the pancreatic tumor cells; and
ii) there is ligand-independent activation in the tumor epithelium as the result of
mutations of the signaling molecules (such as PTC) in the Hh pathway. Aberrant
Hh activity is found throughout the entire PanIN progression and into carcinoma
[84].
Wnt/β-catenin signaling in pancreatic cancer
The Wnt/β-catenin pathway is used in embryonic development similar to
Hh signaling. Briefly, Wnt ligands bind to Frizzled receptors which induce
inactivation of specific cytosolic proteins such as APC that promote β-catenin
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proteosomal degradation.

Without degradation, β-catenin accumulates in the

cytosol then translocates to the nucleus where it promotes transcription of
proteins through binding to TCF/LEF factors [44]. Both cytosolic and nuclear
accumulation of β-catenin has been observed in pancreatic cancer. Inhibiting βcatenin through RNAi severely limits proliferative ability of PDAC.

β-catenin

accumulation in pancreatic cancer may be due to over-expression of Wnt
ligands, but at this time the mechanism remains poorly understood and it isn’t
clear which β-catenins targets are important forpancreatic cancer development
[44, 86]. It is interesting to note is that Wnt signaling appears to be tissue specific
for example, in melanoma, Wnt inhibits Raf/MEK/ERK signaling, but in both
colorectal and pancreatic cancer it activates the oncogenic pathway [86].
Oncogenic signaling mediated by KRAS
KRAS (Kristen-RAS), a member of the RAS family GTP-binding proteins
(GTP-ase), is the most commonly mutated oncogene in PDAC. The RAS family
is known to mediate a large number of important cellular processes such as
proliferation, cell survival and differentiation. RAS proteins are not very efficient
at converting GTP to GDP; therefore, they require a GAP (GTPase Activating
Protein) such as RasGAP (RASA1) to convert GTP to GDP quickly.

After GTP

is then hydrolyzed, the nucleotide must be released from KRAS. A guanine
nucleotide exchange factor or GEF like Son of Sevenless (SOS) takes over this
responsibility releasing the GDP to the cytosol and freeing KRAS to bind to
another GTP.
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The most common mutations in KRAS are activating point mutations
within codon 12. These point mutations are found in around 30% of early PDAC
lesions but are present at 95% to 99% of advanced cases of PDAC [50, 87]. The
activating mutations desensitize KRAS to GAPs or prevent GTP hydrolysis
resulting in a constitutively active KRAS [87-89]. Activating KRAS mutations
initiate tumorigenesis by promoting the formation of PanIN lesions, and recently
murine studies have shown that sustained activation of KRAS is required for
continued progression of PDAC [90].
Activation of KRas leads to sustained activation of key signaling pathways
within the ductal cells including but not limited to the RAF/ERK/MEK pathway and
the PI3K/Akt pathway (Figure 1.4). These mitogenic cellular pathways aid in
crucial oncogenic adaptation such as migratory ability, survival, and increased
proliferation rate [87]. It has been shown recently that activated KRAS enhances
the Warburg effect by elevating pancreatic cancers dependence on aerobic
glycolysis. This metabolic reprogramming is most likely through the activation of
PI3K/Akt pathway and its effector proteins such as HK1, Glut1, and Pfk1 [91].
Changes in the microenvironment in pancreatic cancer are directly linked to
activated oncogenic KRAS as well. Continued inflammatory onslaught to the
pancreas and the immune system activation induces fibrotic and inflammatory
remodeling of the pancreas, which leads to prolonged activation of KRAS [92].
To treat KRAS mutant tumors, combinatorial treatment that inhibits both PI3K/Akt
and MEK/ERK would likely be needed [90].
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Figure 1.4. RAS-mediated activation of both Raf/MEK/ERK and PI3K/Akt
pathway.
This illustration shows the ability of RAS activate both Raf and PI3K two major
oncogenic pathways in pancreatic cancer. Activating KRas mutations allows for
sustained activation of both pathways. This figure is adapted from Mohseni et al.
[93].
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The role of integrin in pancreatic cancer
In order for cells, regardless of type, to migrate they must sustain a
transient interaction between themselves and the substrate to which the cells
adhere to in order to undergo migration. Even transients interaction between the
cell and the substrate is the workings of a consensus of proteins and protein
complexes [94] One of the proteins involved are the Integrins. Integrins are
transmembrane receptors consisting of α and β heterodimers that are capable of
binding the extracellular matrix (ECM) and linking to the intracellular actin
network of the cell [95]. Examples of ECM proteins include laminin, fibronectin,
and collagen. Integrins are found distributed in migrating cells in a polarized
manner, in that increased integrin clustering is found at the leading edge of the
cell where PIP3 levels rise as PI3K activity increases leading to adhesion
formation [94].
It was recently discovered that α6β4-integrin expression is markedly
increased in PDAC, with a step-wise increase in expression through PanIN and
on into carcinoma [96-98]. Integrins not only function as adhesion molecules that
promote migration, but also activate both PI3K/Akt and Raf/MEK/ERK oncogenic
pathways [99, 100]. Integrins activate FAK and SFK proteins upon outside in
activation. This is achieved upon binding of integrins to one of its ligands found in
the ECM (Figure 1.5). The activation of FAK leads to activation of PI3K which in
turn promotes phosphorylation and activation of Akt. SFK proteins activate SHC
which leads to downstream activation of Raf/MEK/ERK and proliferation signals
[101].
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Figure 1.5. Integrin activation leads to activation of PI3K/Akt and
Raf/MEK/ERK pathways.
Integrin activation leads to cell proliferation, survival, and migration through
activation of multiple oncogenic pathways. This figure is adapted from Guo et al.
[101].
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The tumor suppressor role of PHLPP
PHLPP (PH domain leucine-rich-repeats protein phosphatase) belongs to
a novel family of Ser/Thr protein phosphatases that consists of PHLPP1 and
PHLPP2 isoforms. Two splice variants of PHLPP1, PHLPP1α and PHLPP1β,
have been reported, of which PHLPP1β contains an in-frame extension at the Nterminus of PHLPP1α (Figure 1.6) [102, 103]. PHLPP1 has first been proposed
as a regulator of circadium rhythm as the mRNA expression of PHLPP1 in the rat
brain suprachiasmatic nucleus region varies in a circadian-dependent manner.
Thus, it was initially named SCOP for suprachiasmatic nucleus circadian
oscillatory protein [104]. Overexpression of PHLPP1β in mouse forebrain impairs
memory formation in transgenic mice by inhibiting ERK signaling [105].
Importantly, Gao et al. identified PHLPP as the novel protein phosphatase that
directly dephosphorylates Akt and turns off Akt-mediated growth and survival
signaling (Figure 1.7) [106]. PHLPP is then renamed based on its domain
structure as it contains a PH domain, a leucine rich repeat region, a phosphatase
domain, and a PDZ ligand motif (Figure 1.6) [106, 107].
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Figure 1.6. Domain structures of PHLPP1 and PHLPP2 isoforms.
Both PHLPP isoforms contain a PH domain, a leucine rich repeat region (LRR), a
phosphatase domain (PP2C-like phosphatase domain), and a PDZ ligand motif.
Total numbers of amino acids are labeled for each isoform.
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Figure 1.7. PHLPP-mediated dephosphorylation and inactivation of Akt.
Activation of Akt requires membrane translocation and phosphorylation at both
T308 and S473 sites. This PI3K-dependent activation of Akt can be prevented by
PTEN, a lipid phosphatase, which removes the activation signal. PHLPP
inactivates Akt by directly dephosphorylating Akt protein.
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Increasing evidence has indicated that both PHLPP isoforms serve as
tumor suppressors in different types of cancer, which include colorectal, lung,
liver and pancreatic cancer [108-111]. It has been shown that PHLPP negatively
regulates multiple oncogenic pathways by directly dephosphorylating and
inactivating key signaling molecules, such as Akt, S6K, and RAF1 [106-108, 112114]. Moreover, PHLPP promotes the degradation of conventional PKCs by
dephosphorylating the hydrophobic motif of PKC [115]. One interesting caveat is
that Akt is part of this feedback loop with S6K, in which S6K-mediated
phosphorylation of IRS at Ser-302 prevents the association of IRS with IGFR and
downregulates IRS protein, thus, preventing activation of Akt following IGFR
activation [116]. PHLPP also regulates the negative feedback loop of Akt by
dephosphorylating S6K and decreasing its activity [113].
PHLPP is frequently downregulated in colorectal cancer patients and
reintroduction of PHLPP into colon cancer cells inhibits cell proliferation, in vitro,
and tumorigenesis in nude mice [108]. Recently, Li et al. demonstrated that
PHLPP is a negative regulator of the RAS/RAF pathway by directly
dephosphorylating RAF1 and inhibiting its kinase activity. Knockdown of PHLPP
enhances signaling through the RAF/MEK/ERK cascade, induces EMT, and
increases cell migration and invasion [117]. Genetic deletion of PHLPP1
promotes the development of invasive intestinal adenocarcinoma and decreases
survival in ApcMin mice [117]. In pancreatic cancer, PHLPP expression is reduced
in PanIN lesions compared to normal controls, and is almost entirely lost in
PDAC tissues [118].
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This correlates with increasing phosphorylation of Akt through different
PanIN stages to PDAC [118]. Collectively, PHLPP provides a balance in both
Raf/MEK/ERK and PI3K/Akt pathways; and loss of PHLPP leads to aberrant
activation of these pathways giving rise to cells that are able to proliferate
unchecked while having an increase in ability to migrate (Figure 1.8).
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Figure 1.8. PHLPP plays a pivotal role in controlling the signaling balance
of both PI3K/Akt and RAS/RAF pathways.
These two oncogenic pathways, PI3K/Akt and Raf/MEK/ERK pathways, are
exploited during turmorigenesis and metastasis. PHLPP is a converging point
that regulates both.

44

Significance of this study
Increasing numbers of studies have indicated that PHLPP plays an
important role in turning off major oncogenic signaling pathways [119]. The
majority of these studies have focused on colorectal cancer and revolved around
the oncogenic kinase Akt. Recent studies show PHLPP not only regulates the
activity of the PI3K/Akt pathway, but also has the ability to inhibit the
Raf/MEK/ERK pathway by dephosphorylating RAF1. These two pathways play
central roles in PanIN lesion development and especially PDAC formation, and
close to 95% of PDAC metastatic tumors are found to have active KRAS
mutations. Given the extremely low survival rates of pancreatic cancer, new
diagnostic and treatment strategies are urgently needed in order to improve
patient survival in pancreatic cancer.
In this study, we investigated how the change in expression of PHLPP
regulated PI3K/Akt and RAF/MEK/ERK signaling in PDAC cells. We discovered
that PHLPP negatively regulates the migratory ability of PDAC. After differing
PHLPP levels of expression in pancreatic cancer cells we noticed that α4β6
integrin expression was significantly altered. This may be through PHLP
regulating the lysosomal mediated degradation pathway of integrins. Our study
establishes a novel link between PHLPP, Akt, and integrin. Better understanding
of how PHLPP functions as a tumor suppressor and the underlying molecular
mechanism may help to identify new therapeutic targets in pancreatic cancer.
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Chapter 2. Methods and Materials

Cells and reagents
The following pancreatic ductal adenocarcinoma cell lines, ASPC-1, Panc1, and Suit-2, were kindly provided by Dr. Kathleen O’Connor (University of
Kentucky). The Panc-1 cells used in this study were sorted for their high integrin
expression as described previously [120]. Panc-1 cells were cultured in DMEM
whereas ASPC-1 and Suit-2 cells were cultured in RPMI-1640. All media were
supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich) and 1%
penicillin/streptomycin.
The shRNAs for human PHLPP1, PHLPP2, AKT1 and AKT2 genes used
in this study were constructed in pLKO.1-puro vector and purchased from SigmaAldrich [121]. The targeting sequences are as the following: PHLPP1, 5’PHLPP2,

CGAGGTCTTTCCCGAAGTTAT-3’,

5’-

GCCTGAACTTGTCCCATAATA-3’, AKT1, 5’-GGACAAGGACGGGCACATTAA3’ and AKT2, 5’- CCCTTAAACAACTTCTCCGTA-3’. A plasmid carrying a nontargeting sequence was used to create the control cells. For virus packaging, the
control or gene-specific shRNA constructs were co-transfected with psPAX2 and
pMD2.G packing plasmids (Addgene) into 293T cells using polyethylenimine
(PEI). The virus containing media were collected, filtered, and overlaid onto
pancreatic cells in the presence of polybrene (8 μg/ml). The infected cells were
then subjected to selection with puromycin (1 μg/ml). To overexpress human
PHLPP1 or PHLPP2, the retroviral expression plasmids, including pBabe-puroHA-PHLPP1β and pBabe-puro-HA-PHLPP2, were described previously [108,
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114]. The stable PHLPP overexpressing cells were generated by infecting cells
with retrovirus encoding HA-PHLPP1β or HA-PHLPP2 and selecting with
puromycin (1 μg/ml).
PHLPP1 and PHLPP2 antibodies were obtained from Proteintech and
Bethyl Laboratories, respectively. The phospho-Akt (p-Akt for the Ser473 site),
phospho-ERK1/2 (p-ERK for Thr202/Tyr204), phospho-MEK1/2 (p-MEK for
Ser217/221), EGFR and E-cadherin antibodies were from Cell Signaling. The
vimentin antibody was from BD Biosciences whereas the γ-tubulin antibody was
from Sigma-Aldrich. The following integrin antibodies were used in this study: for
Western blotting, anti-β1 rabbit mAb (D2E5, Cell Signaling) and anti-β4 mouse
mAb (clone 7, BD Biosciences); and for blocking ECM binding, anti-β1 mouse
mAb (clone 6S6, Millipore) and anti-β4 mouse mAb (clone ASC-8, Millipore). The
following chemicals, including PI3K inhibitor LY290042, rapamycin, PP242 and
Akt inhibitor VIII, were purchased from EMD/CalBiochem. The MEK1/2 inhibitor
PD0325901 was purchased from Selleck Chemicals, and lysosome inhibitors
bafilomycin A1 and cycloheximide were from Sigma-Aldrich.

Immunoblotting
Cultured cells were harvested and lysed in Lysis Buffer (50 mM Na 2HPO4,
1 mM sodium pyrophosphate, 20 mM NaF, 2 mM EDTA, 2 mM EGTA, 1% Triton
X-100, 1 mM DTT, 200 mM benzamidine, 40 mg ml-1 leupeptin, 200 mM PMSF)
and the detergent-solublized cell lysates were obtained after centrifugation for 5
minutes at 16,000 g at 4 oC. Equal amounts of cell lysates as determined by
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Bradford assays were resolved by SDS-PAGE and subjected to immunoblotting
analysis. The density of ECL signals was obtained and quantified using a
FluoChem digital imaging system (Alpha Innotech).

Wound Healing Assay
Cultured cells were plated in a 6 well plate in their respective media.
Using a 200uL pipette tip a wound was made through the center of each well.
The cells were washed with cold 1XPBS three times to rinse away any nonattached cell. The plate was placed in the incubator for 24 hours. Pictures were
taken at time 0 and at 24 hours. The diameter of the wound was measured at
time 0 and time 24 hours.

The percent wound healed was calculated by

migration of the cells closing the gap or wound.

Transwell migration assays
Serum starved pancreatic cancer cells were seeded into the upper
chamber of Transwell inserts with an 8-m pore size membrane (Corning). For
migration assays, the bottom of the inserts were coated with collagen (15 g/ml)
or laminin (25 μg/ml), and the cells were allowed to migrate towards media
containing either HGF (20 ng/ml) or IGF-1 (20 ng/ml) in the lower chamber for 25 hours. At the end of the incubation period, Transwell inserts were fixed in
methanol and stained with 0.5% crystal violet. The numbers of cells that were
migrated to the lower chamber of the Transwell were counted using an inverted
microscope at 20X magnification.
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Time-lapse live cell imaging and analysis
Stable control and PHLPP overexpressing Panc-1 cells and PHLPP
knockdown ASPC-1 cells were serum starved for 2 hours and seeded as single
cells onto collagen (15 g/ml) or laminin (25 g/ml) coated glass bottom culture
dishes (MatTek). The migration of live cells was recorded in media containing
HGF (20 ng/ml) using Nikon BioStation IM equipped with CO 2 incubation
chamber. Time-lapse phase images were taken either every 5 or 10 minutes for
6 hours with a 20X objective. The movement of cells was tracked and analyzed
using Nikon Element AR software.

3D cell culture
Single cell suspension of pancreatic cancer cells was prepared in serum
free media and embedded into collagen/Matrigel (1:1) mixture. The cells were
overlaid with 2% Matrigel in 2% FBS containing media. The cells were allowed to
grow into cyst-like structures in the 3D matrix for 1-2 weeks. The size and
morphology of the cysts were examined by phase-contrast microscopy using a
Nikon Ti-E inverted microscope. For immunofluorescence staining, the cysts
were fixed in 4% paraformaldehyde and permeabilized using 1% Triton X-100 in
PBS. Actin was stained using Alexa 488-conjugated phalloidin while the nuclei of
the cells were stained with DAPI-containing mounting medium. Cells were
visualized using an Olympus FlowView FV1000 confocal laser-scanning
microscope.
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Immunofluorescence (IF) staining
IF staining was performed following procedures described previously
[122]. Briefly, stable control and PHLPP overexpressing Panc-1 cells and PHLPP
knockdown ASPC-1 cells were serum starved for 2 hours and seeded as single
cells onto collagen (15 g/ml) coated coverslips and allowed to attach for 20
minutes. The cells were then fixed in 4% paraformaldehyde and followed by
incubating with labeling buffer (1% bovine serum albumin in phosphate-buffered
saline, pH 7.4) to block nonspecific binding. In labeling buffer the antibody
specific for anti-β4-integrin antibody from BD biosciences was diluted and added
to the cells for 2 hour incubation. The cells were then washed 3 times for 5
minutes each wash with 1XPBS. Alexa 488-conjugated phalloidin and Alexa 594
fluorescent dye were diluted in labeling buffer and incubated with the cells for 1
hour. The basolateral distributions of F-actin were visualized using a Nikon laser
TIRF (Total Internal Reflection Fluorescence) microscope.

Real-time PCR
Total RNA was isolated with RNeasy kit (Qiagen) from different stable
pancreatic cancer cell lines. Equal amounts of RNA were used as templates for
the synthesis of cDNA using High Capacity cDNA Reverse Transcription kit
(Applied Biosysems). Real-time PCR reaction was performed using the StepOne
Real-Time PCR system (Applied Biosysems) with β1- and β4-specific probes. All
values were normalized to the level of β-actin.
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Statistical Analysis
The results from the experiments to assess the rate of migration, levels of
protein and mRNA expression, cell growth in 3D, and velocity and distance
migrated by single cells were summarized using mean ± SEM or mean ± SD. All
experiments were performed in triplicate and pairwise comparisons were carried
out using two-sample t-tests. Statistical significance of values among different
groups was set at p < 0.05.
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Primer:
CD29 (Igβ1)
Forward
CD29 (Igβ1)
Reverse
CD104 (Igβ4)
Forward
CD104 (Igβ4)
Reverse

Designation:
Sequence:
β1-Integrin Primer TGACCATCTCTTCTCCTCTCCAC
β1-Integrin Primer GGAGTCACACTGGTCAACAGAG
Β4-Integrin
Primer
Β4-Integrin
Primer

AAAAAGGATTGAGTTCCTTGCAAAAA
CCCAGAGTCTTGTGGTTCTCTAAC
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Table 2.1: Primers used for qRT-PCR
Primers for both β4 integrin and β1 integrin were used in qRT-PCR studies.
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Chapter 3
Results

Introduction
Accumulation of genetic mutations in oncogenes and tumor suppressors
lead to the development of pre-malignant lesions which eventually through
genetic instability give rise to carcinoma within the pancreatic ductal epithelium
[123]. Thus, a better understanding of the molecular events leading to cancer
progression is needed in order to improve the treatment and prognosis of PDAC
patients. Key mutations in oncogenes such as KRAS with deactivation of tumor
suppressor genes SMAD4 and CDKN2A/INK4A have been implicated in the
development and progression of pancreatic cancer [47, 124]. In addition, it has
been shown that overexpression of integrin α6β4 promotes migration and
invasion of pancreatic cancer cells and is associated with the progression of
PDAC [97, 120]. Integrins are known to contribute to tumor progression and
metastasis by directly activating a number of oncogenic signaling pathways,
including PI3K/Akt and RAS/RAF pathways, in various types of cancer [99, 100].
However, the molecular mechanism by which the expression of integrin proteins
is regulated remains elusive in pancreatic cancer cells.
PHLPP (PH domain leucine-rich repeat protein phosphatase) belongs to a
novel family of Ser/Thr protein phosphatases. There are two isoforms, PHLPP1
and PHLPP2, identified in this family [102, 103, 106, 107]. Both PHLPP isoforms
were first discovered as the phosphatases for Akt that directly dephosphorylate
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the hydrophobic motif Ser473 site and inactivate the kinase [106, 107]. Moreover,
it has been shown that PHLPP dephosphorylates Ser338, a key activation site on
RAF1, and inhibits the downstream signaling through RAF/MEK/ERK in colon
cancer cells [114]. Therefore, PHLPP may exert its tumor suppressor function by
negatively regulating both the PI3K/Akt and RAS/RAF pathways. Recently,
Nitsche et al discovered that there is a stage-dependent downregulation of
PHLPP in pancreatic cancer patient specimens, thus suggesting a tumor
suppressor role of PHLPP in pancreatic cancer [111]. However, it remains
unknown whether loss of PHLPP expression promotes cancer cell migration in
pancreatic cancer.
In this study, we investigated the effect PHLPP expression had on cell
migration and motility in pancreatic cancer cells.. We identified a novel
connection between PHLPP expression and integrin function. Results from our
study revealed that PHLPP-loss increases cell motility by upregulating integrin
expression and inducing EMT. Furthermore, this regulation of integrin expression
mediated by PHLPP may be through lysosomal degradation of integrin,
specifically β4 and β3 integrin.

PHLPP negatively regulates the activity of Akt and MEK/ERK in pancreatic
cells
To determine if PHLPP negative regulates both the PI3K/Akt and
Raf/MEK/ERK pathway in human pancreatic cancer, we established stable cell
lines overexpressing PHLPP1 or PHLPP2 in Panc-1 cells, which express very
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low levels of endogenous PHLPPs. The PHLPP1 gene potentially encodes two
differentially spliced variants, PHLPP1α and PHLPP1β [102]. Since the longer
transcript

of

PHLPP1,

PHLPP1β,

is

the

predominant

form

expressed

endogenously in all pancreatic cell lines examined, we used PHLPP1β in our
study. We first determined the effect of PHLPP overexpression on cell signaling.
As shown in Figure 3.1, both Akt and MEK/ERK activity were downregulated in
PHLPP overexpressing cells compared to control cells as indicated by decreased
phosphorylation of Akt, MEK, and ERK. Next, to determine the effect of
endogenous PHLPP on inhibiting Akt and MEK/ERK signaling, PHLPP was
silenced in ASPC-1 cells, which express relatively higher levels of endogenous
PHLPPs, using lentiviral-mediated RNAi. Immunoblotting results revealed that
phosphorylation of Akt, MEK, and ERK was significantly elevated when PHLPP
expression was knocked down (Figure 3.2). Consistent with previous reports on
the tumor suppressor function of PHLPP in other cancer types [108, 114, 125127], our results here provide the initial evidence that PHLPP is capable of
inhibiting both Akt and MEK/ERK signaling in pancreatic cancer cells.
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Figure 3.1. Overexpression of PHLPP isoforms inhibits PI3K/Akt and
MEK/ERK signaling.
(A) Stable control, HA-PHLPP1β or HA-PHLPP2 overexpressing Panc-1 cells
were generated using retrovirus-mediated infection. The cell lysates were
prepared and analyzed for phosphorylation and total protein expression by
immunoblotting. (B) Relative phosphorylation for p-Akt, p-MEK, p-ERK were
calculated and normalized to those of total Akt, MEK and ERK, respectively. The
level in control cells was set to 1. Data represent the mean ± SEM (n=3, * p<0.05
by two-sample t-tests).
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Figure

3.2.

Loss

of

PHLPP

expression

enhances

PI3K/Akt

and

RAF/MEK/ERK signaling.
(A) Stable control (sh-Con) and PHLPP knockdown (sh-PHLPP1 and shPHLPP2) ASPC-1 cells were generated using lentivirus-mediated RNAi. The cell
lysates were analyzed for phosphorylation and total protein expression by
immunoblotting. (B) Relative phosphorylation for p-Akt, p-MEK, p-ERK were
calculated and normalized to those of total Akt, MEK and ERK, respectively.
The level in control cells was set to 1. Data represent the mean ± SEM (n=3, *
p<0.05 by two-sample t-tests).
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PHLPP negatively regulates cell migration in pancreatic cancer cells
Previous studies of PHLPP expression in colorectal cancer cells showed
an enhanced ability for PHLPP knockdown cells to migrate and transition into
EMT [114]. To test if PHLPP regulates cell motility in pancreatic cancer cells, we
first examined the expression of EMT markers in PHLPP overexpressing Panc-1
and PHLPP knockdown ASPC-1 cells. As shown in Figure 3.3, PHLPP
overexpression markedly increased the expression of E-cadherin, an epithelial
cell marker, and decreased the expression of vimentin, a mesenchymal cell
marker. Conversely, knockdown of either PHLPP isoform decreased E-cadherin
whereas increased vimentin expression (Figure 3.3), suggesting that PHLPP
downregualtion promotes EMT in pancreatic cancer cells.
To begin the initial study of migration in pancreatic cancer we investigated
the ability of PHLPLP overexpressing Panc-1 cells to heal a wound introduced
into the cultured cells. Figure 3.4 shows the significant difference in ability of the
PHLPP overexpressing cells to close the gap after the wound was introduced
compared to the control cells. By 24 hours post scratch the control pancreatic
cancer Panc-1 cells had healed the wound by 90% but the PHLPP
overexpressing cell lines had about a 40-45% gap closure. This was the first hint
that PHLPP could influence the migratory ability of pancreatic cancer cells.
Furthermore, to determine if PHLPP regulates pancreatic cancer cell
migration. PHLPP overexpressing Panc-1 cells and PHLPP knockdown ASPC-1
cells were subjected to Transwell migration assay. We found that PHLPP
overexpressing cells migrated significantly slower than the control cells as
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determined by Transwell migration assays (Figure 3.5). In contrast, knockdown
of PHLPP significantly enhanced the ability of pancreatic cancer cells to migrate
in response to HGF. Similar results were obtained when using IGF-1 and
collagen were used as chemoattractants (Figure 3.6). Taken together, we have
identified a role of PHLPP in inhibiting EMT and cell motility in pancreatic cancer
cells.
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Figure 3.3. Knockdown of PHLPP expression induces EMT phenotype in
pancreatic cancer cells.
Cell lysates were prepared from stable control and PHLPP overexpressing Panc1 as well as PHLPP knockdown ASPC-1 cells.

The expression levels of E-

cadherin and vimentin were analyzed using immunoblotting.
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Figure 3.4. PHLPP inhibits the ability of pancreatic cancer cells to heal a
wound.
Panc-1 cells were plated in a 6-well plate, a wound was introduced by scratching
the cells off using a 200uL pipette tip. The diameter of the wound was measured
at time 0 and 24 hour.

Each experiment was done in duplicates and three

independent experiments were averaged and expressed as mean  SEM (*
p<0.05 by two-sample t-tests compared to the control cells).

66

67

Figure 3.5. PHLPP negatively regulates pancreatic cancer cell migration.
Stable control and PHLPP overexpressing Panc-1 cells and stable control and
PHLPP knockdown ASPC-1 cells were subjected to Transwell migration assays
using HGF and laminin as chemoattractants. The inserts shown were
representative images of cells migrated in the Transwell assays. Each
experiment was done in duplicate and three independent experiments were
averaged and expressed as mean  SEM (* p<0.05 by two-sample t-tests
compared to the control cells).

68

69

Figure 3.6. Migration of pancreatic cancer cells is amplified when PHLPP
expression is lost.
Stable control and PHLPP knockdown ASPC-1 cells were subjected to Transwell
migration assays using either HGF and collagen (A) or IGF-1 (20 ng/ml) and
laminin (B) as chemoattractants. Each experiment was done in duplicate and
three independent experiments were averaged and expressed as mean  SD (*
p<0.05 by two-sample t-tests compared to the control cells).
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We next determined the effect of PHLPP on modulating cell motility at the
single cell level. To this end, PHLPP overexpressing Panc-1 and PHLPP
knockdown ASPC-1 cells were subjected to cell tracking experiments to monitor
the cell movement in real time. The Biostation allows for pictures to be taken at
specific intervals, which then can be used to track each individual cells migration.
Stable control and PHLPP overexpressing or knockdown cells were seeded on
glass-bottom plates coated with laminin, starved, then stimulated with HGF. We
found that overexpression of PHLPP resulted in a significant decrease in cell
motility when compared to control cells (Fig. 3.7A). The velocity and average
distances traveled were significantly decreased in PHLPP overexpressing cells
as well (Fig. 3.7B-C). To determine the effect of silencing the endogenous
PHLPP expression at the single cell level, similar experiments were performed
using control and PHLPP knockdown ASPC-1 cells. We found that PHLPP
knockdown cells were considerably more motile (Fig. 3.8), and the velocity and
average distances traveled were significantly increased in PHLPP knockdown
cells (Fig. 3.8B-C). Taken together with results obtained in Transwell migration
assays, we showed that PHLPP expression negatively impacts single cell
migration and velocity. Since increased motility is often associated with increased
aggressiveness in order for pancreatic cancer cells to metastasize, our data
provide evidence supporting the tumor suppressor role of PHLPP.
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Figure 3.7. PHLPP inhibits cell motility at the single cell level.
(A) Migration patterns of stable control and PHLPP overexpressing Panc-1 cells
on laminin coated plates using HGF as the chemoattractant. The trajectories of
12 randomly chosen cells for each cell line were plotted in the graphs. (B-C) The
average distance traveled (B) and the relative velocity (C) of 12 stable control
and PHLPP overexpressing Panc-1 cells during 6 hours of migration. Data
represent mean  SD (n = 12 cells/line, * p<0.05 by two-sample t-tests).
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Figure 3.8. Knockdown of PHLPP increases cell motility at the single cell
level.
(A) Migration patterns of stable control and PHLPP knockdown ASPC-1 cells on
laminin coated plates using HGF as the chemoattractant. The trajectories of 12
randomly chosen cells for each cell line were plotted in the graphs. (B-C) The
average distance traveled (B) and the relative velocity (C) of 12 stable control
and PHLPP knockdown ASPC-1 cells during 6 hours of migration are shown.
Data represent mean ± SEM (n = 12 cells/line, * p<0.05 by two-sample t-tests).
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PHLPP inhibits the invasive growth of pancreatic cancer cells in 3D culture
EMT requires the process of cancer cells sending extensions away from
the cell body in order to migrate. To further determine the effect of PHLPP on
invasive growth of pancreatic cancer cells, we used 3D cell culture systems as
they closely mimic the cancer microenvironment and they provide a better
opportunity to explore the effects of oncogenes and tumor suppressors on
modulating morphogenesis as well as invasive growth [128, 129]. Both PHLPP
overexpressing Panc-1 and PHLPP knockdown ASPC-1 cells were seeded into
Matrigel and allowed to grow for up to 7 days. The control Panc-1 cells grew into
large multi-globular clusters with spikes of membrane protrusions extending into
Matrigel (Figure 3.9A-B). However, the formation of membrane protrusions was
completed blocked in PHLPP overexpressing cells and the size of cell clusters
was significantly decreased. (Figure 3.9C)
Although no clear membrane protrusions were observed in ASPC-1 cells
grown in Matrigel, PHLPP knockdown cells formed significantly larger globular
clusters compared to the control cells, suggesting that PHLPP-loss increases the
invasive growth ability of pancreatic cancer cells (Figure 3.10)
In addition, TIRF (Total Internal Reflection Fluorescence) imaging was
incorporated into our studies to look at formation of stress fibers, extensions, and
integrin expression. Control Panc-1 cells showed the formation of both stress
fibers and long filamentous extensions at the basolateral membrane surrounding
the entire cells whereas very few actin stress fibers were observed in PHLPP
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overexpressing cells (Figure 3.11). Integrin staining in PHLPP overexpressing
cells seems to be located more centrally to the cell possibly closer to the nucleus
of the cell instead of at the extensions compared to control. The reduction of
integrin expression at the extensions and protrusions could possibly negatively
affect migration and cell motility. However, when ASPC-1 cells were stained for
both actin and integrin it is apparent that there are major filamentous extensions,
large protrusions from the basolateral membrane surrounding the cells and the
most interesting aspect is the large amount of integrin staining at the basolateral
membrane and protrusions (Figure 3.12). ASPC-1 control cells have nice actin
stress ring formation and integrin staining inside of the stress ring, but still in
punctate formation (Figure 3.12), unlike the Panc-1 overexpressing cells where
the integrin staining is more diffuse and less punctate (Figure 3.11). In the
ASPC-1 PHLPP knockdown cells integrin staining is most noticeable at the
protrusions and filamentous extensions seen coming from the basolateral
membrane.

The β4-integrin staining is punctate in pattern and seems to be

deposited outside of the cell membrane giving a unique arrangement (Figure
3.12). Collectively, these results showed that decreased PHLPP expression
alters actin cytoskeleton rearrangement and increases invasive growth of
pancreatic cancer cells.
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Figure 3.9. PHLPP inhibits the invasive phenotype of pancreatic cancer
cells grown in 3D culture.
Stable control and PHLPP overexpressing Panc-1 cells were seeded in Matrigel
and allowed to grow for 7 days. On the 3rd day (Top panel) and the 7th day
(Bottom panel) after seeding phase contrast images were taken with the 10X
objective on using an inverted Nikon microscope. The boxed regions were
enlarged and shown next to the original images. Scale bars, 100 μm. (C) The
size of cell clusters at day 7 was measured and analyzed using Nikon Element
AR software. Data represent mean ± SEM (n = 18 cells/line, * p < 0.05 by twosample t-tests).
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Figure 3.10. Knockdown of PHLPP promotes the invasive growth of
pancreatic cancer cells in 3D culture.
Stable control and PHLPP knockdown ASPC-1 cells were seeded in Matrigel and
allowed to grow for 7 days. On the 5th day (A) and the 7th day (B) after seeding
phasecontrast images were taken with the 10X objective on using an inverted
Nikon microscope. Scale bars, 100 μm. (C) The size of cell clusters at day 7 was
measured and analyzed using Nikon Element AR software. Data represent mean
± SEM (n = 18 cells/line, * p < 0.05 by two-sample t-tests).
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Figure 3.11. PHLPP affects actin cytoskeleton dynamic in pancreatic cancer
cells.
Stable control and PHLPP overexpressing Panc-1 cells were seeded onto
collagen coated cover slips in serum-free media. After 20 minutes of incubation
at 37oC the cells were fixed with 4% paraformaldehyde, blocked with anti-goat
serum, incubated with β4-integrin antibody, and stained with Alexa488-phalloidin
and Alexa 594 anti-mouse dye. TIRF images were from the basolateral
membrane of the cells and two representative images are shown for each cell
line (scale bars, 20 μm).
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Figure 3.12. Knockdown of PHLPP affects integrin localization in pancreatic
cancer cells.
Stable control and PHLPP overexpressing Panc-1 cells were seeded onto
collagen coated cover slips in serum-free media. After 20 minutes of incubation
at 37oC the cells were fixed with 4% paraformaldehyde, blocked with anti-goat
serum, incubated with β4-integrin antibody, and stained with Alexa 488-phalloidin
and Alexa 594 anti-mouse dye. TIRF images were from the basolateral
membrane of the cells and two representative images are shown for each cell
line (scale bars, 20 μm).
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PHLPP regulates the expression of integrin in pancreatic cancer cells
Previous studies have shown that increased β4 integrin expression is
associated with pancreatic cancer progression [97]. Interestingly, when
examining the expression of β integrin using Western blotting analysis, we found
that the expression of both β4 and β1 integrin was significantly reduced in PHLPP
overexpressing Panc-1 cells, suggesting that increased expression of PHLPP
suppresses integrin expression. On the other hand, knockdown of PHLPP in
ASPC-1 cells results in a significant increase in the expression of both β4 and β1
integrin (Figure 3.13).
To further determine if PHLPP-mediated regulation of β4 and β1 integrin
expression is controlled at the transcriptional level, total RNAs were isolated from
PHLPP overexpressing Panc-1 and PHLPP knockdown ASPC-1 cells, and
quantitative real-time PCR (qRT-PCR) analysis was performed using probes
specific for the β4 or β1 integrin gene. The results revealed that the mRNA levels
of β4 and β1 integrin were not significantly altered by changes in PHLPP
expression (Figure 3.14). Interestingly, the mRNA expression of β1 integrin was
increased in PHLPP1β overexpressing cells. However, since the expression of β1
integrin protein was decreased, this increase in mRNA expression unlikely
contributes to PHLPP induced downregulation of β1 integrin. Collectively, these
results indicated that PHLPP negatively regulates integrin expression via a posttranslational mechanism in pancreatic cancer cells.
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Figure 3.13. Integrin protein expression inversely changes in regard to
PHLPP expression.
(A) Cell lysates prepared from PHLPP overexpressing Panc-1 and PHLPP
knockdown ASPC-1 cells were analyzed for the expression of β1 and β4 integrin
and tubulin using immunoblotting. (B-C) Relative expression of β1 (B) and β4
integrin (C) was calculated and normalized to tubulin. The level in control cells
was set to 1. Data represent the mean ± SEM (n=3, * p<0.05 by two-sample ttests).
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Figure 3.14. Integrin mRNA expression is not altered relative to PHLPP
expression.
Total RNAs were isolated from PHLPP overexpressing Panc-1 cells (A) and
PHLPP knockdown ASPC-1 cells (B). Quantitative real-time PCR analysis was
performed using probes specific for human β1 and β4 integrin genes. Each
experimental point was done in triplicates, and the graphs represent the mean ±
SD (n=3).
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Figure 3.15. EGFR protein expression mirrors integrin protein expression
in response to PHLPP activity.
Cell lysates prepared from PHLPP overexpressing Panc-1 and PHLPP
knockdown ASPC-1 cells were analyzed for the expression of EGFR, PHLPP1,
PHLPP2 and tubulin using immunoblotting.
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Interestingly, we found that not only was integrin expression altered when
PHLPP expression was changed so was EGFR (Figure 3.15).

EGFR is an

oncogene that is commonly activated in many cancers including pancreatic
cancer [77, 79, 81-83]. Activation of EGFR in pancreatic cancer can also be
achieved via increased secretion of EGFR ligands by the tumor cells themselves
[83]. Co-localization of EGFR with integrin has been reported in the lipid rafts
suggesting common mechanisms may control the protein expression of both
EGFR and integrins [130].
To further investigate the mechanism by which PHLPP regulates integrin
expression, we tested if the PI3K/Akt or the MEK/ERK pathway is involved in
controlling the expression of integrin proteins. Inhibiting the PI3K/Akt pathway
using a PI3K inhibitor, LY294002, in ASPC-1 cells resulted in an approximately
40% reduction in both β4 and β1 integrin expression over time (Figure 3.16A-B).
PP242, an inhibitor of PI3K and mTOR, is able to reduce integrin expression in
ASPC-1 cells. However, this was not seen when rapamycin, an mTOR inhibitor,
was used to treat the pancreatic cancer cells (Figure 3.16 C). Similar decrease
of integrin expression was seen in cells treated with an Akt inhibitor, Akt-VIII
(Figure 3.16D). In contrast, treating cells with a MEK inhibitor, PD325901, did
not alter the expression of integrin (Figure 3.17A), suggesting that PHLPPinduced downregulation of integrin is likely mediated through inhibition of Akt
signaling. As a control, we found that the mRNA levels of integrin were not
significantly changed in cells treated with LY294002 (Figure 3.17B).
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To further validate the influence that PI3K/Akt pathway has over integrin
expression, we stably knocked down either Akt1 or Akt2 in ASPC-1 cells. In Akt
knockdown cells both β4 and β1 integrin expression was greatly reduced
compared to control (Figure 3.18). Just as seen previously in PHLPP
overexpressing cells (Figure 3.15), EGFR protein expression was markedly
reduced in Akt knockdown pancreatic cancer cells. Interestingly, knockdown of
Akt induced mesenchymal-epithelial transition (MET), the reverse process of
EMT, in ASPC-1 cells as indicated by increased E-cadherin and decreased
vimentin expression. Similar results were observed in PHLPP overexpressing
cells (Figure 3.3). Taken together, our findings suggested that PHLPP negatively
regulates β4 and β1 integrin expression likely through inhibition of Akt activity in
pancreatic cancer cells.
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Figure 3.16. Inhibition of PI3K/Akt pathway decreases integrin expression.
(A) ASPC-1 cells were incubated with LY294002 for 0-12 hours. At indicated time
points, cell lysates were prepared and analyzed for the expression of β1 and β4
integrin and tubulin using immunoblotting (B) Relative expression of β1 and β4
integrin at different time points following LY294002 treatment in ASPC-1 cells
was calculated and normalized to tubulin. The level in untreated cells was set to
1. Data represent the mean ± SEM (n=3, * p < 0.05 by two-sample t-tests). (C)
ASPC-1 cells were incubated with PP242 or rapamycin for 0-12 hours. At
indicated time points, cell lysates were prepared and analyzed for the expression
of β1 and β4 integrin and tubulin using immunoblotting. (D) ASPC-1 cells were
incubated with AKT VIII, LY294002, and Rapamycin for 8 hours. Cell lysates
were prepared and analyzed for the expression of β4 integrin, p-AKt, and tubulin
using immunoblotting.
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Figure 3.17. The effect of inhibiting PI3K/Akt and MEK/ERK signaling on the
expression of integrins in pancreatic cancer cells.
(A) ASPC-1 cells were treated with DMSO, LY294002 or PD0325901 for 16
hours. Cell lysates were prepared and analyzed for the expression of β4 integrin
and tubulin using immunoblotting. (B) Panc-1 cells were treated with LY204002
(20 nM) for 4 or 8 hours and total RNAs were extracted. Real-time PCR analysis
was performed using probes specific for human β4 integrin gene. Each
experimental point was done in triplicates, and the graphs represent the mean ±
SD (n=3).
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Figure 3.18. Knockdown of Akt decreases the expression of integrin in
pancreatic cancer cells.
Cell lysates prepared from sh-control, sh-Akt1 and sh-Akt2 ASPC-1 cells were
analyzed for the expression of β1 and β4 integrin. The expression of EGFR,
pERK, E-cadherin, vimentin and tubulin was also analyzed using immunoblotting.
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Blocking integrin activity inhibits PHLPP-loss induced increase in cell
motility
To determine the functional impact of PHLPP-mediated inhibition of
integrin expression, we examined the rate of cell migration in control and PHLPP
knockdown ASPC-1 cells in the presence of blocking antibodies against β4 or β1
integrin. As shown in Figure 3.19A, incubating cells with either β4 or β1 integrin
blocking antibodies significantly reduced cell migration in both control and
PHLPP knockdown cells as measured by Transwell assays. Moreover, inhibiting
integrin activation impaired cell motility at the single cell level as the relative
velocity in the control and PHLPP knockdown cells became indistinguishable
after the blocking antibody treatment (Figure 3.19B). These data suggested that
increased integrin expression in PHLPP knockdown cells is responsible for
increased cell migration.
We then assessed the ability of Akt knockdown ASPC-1 cells to migrate in
response to HGF. Surprisingly, Akt knockdown cells had enhanced migratory
ability when compared to control cells (Figure 3.20). This paradoxical effect of
Akt on cell migration has been reported in breast cancer cells in which Aktmediated inhibition of NFAT activity has been indicated as the underlying
molecular mechanism [131, 132]. In addition, when treating Akt knockdown cells
with β1-integrin blocking antibody, the ability of control cells to migrate was
significantly inhibited as described in Figure 3.19. However, the β1-integrin
blocking antibody was unable to block migration of Akt knockdown cells (Figure
3.20). Interestingly, we found the activation of ERK was increased in Akt
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knockdown cells (Figure 3.20). This activation of ERK may mediate the integrinindependent effect of silencing Akt on cell migration in pancreatic cancer.
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Figure 3.19. The PHLPP-mediated regulation of cell migration relies on its
ability to control integrin expression.
(A) Stable control and PHLPP knockdown ASPC-1 cells were subjected to
Transwell migration analysis using HGF as the chemoattractant. To block integrin
activation, ASPC-1 cell suspensions were incubated with blocking antibodies of
β1 or β4 integrin in serum-free media containing 1% BSA for 20 minutes at 4 °C.
The cells were then seeded onto the collagen coated Transwells in the presence
of the blocking antibodies and allowed to migrate for 4 hours at 37°C. Each
experiment was done in duplicate and three independent experiments were
averaged and expressed as mean  SEM (* p<0.01 by two-sample t-tests
compared to the control cells). (B) Cells as treated as above with blocking
antibodies were monitored for single cell motility using time-lapse imaging. The
cells were allowed to migrate in response to HGF for 6 hours. The average
velocities of 12 cells from each group are shown. Data represent mean ± SEM (n
= 12 cells/line, * p<0.05 by two-sample t-tests).
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Figure 3.20. The effect of Akt knockdown on cell migration in pancreatic
cancer cells.
(A) Stable control and Akt knockdown ASPC-1 cells were subjected to Transwell
migration assays using HGF as chemoattractant. To block integrin activation,
ASPC-1 cell suspensions were incubated with the β1 integrin blocking antibody in
serum-free media containing 1% BSA for 20 minutes at 4 °C. The cells were then
seeded onto the collagen coated Transwells in the presence of the blocking
antibodies and allowed to migrate for 4 hours at 37°C. Each experiment was
done in duplicate and three independent experiments were averaged and
expressed as mean  SEM (* p<0.01 by two-sample t-tests compared to the
control cells). (B) Cell lysates prepared from control and Akt knockdown ASPC-1
cells were analyzed using immunoblotting.
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Integrin expression is controlled through lysosomal degradation in
pancreatic cancer cells
Recent studies have suggested that integrins can be internalized upon
binding to extracellular matrix (ECM) ligands and trafficked to lysosome for
degradation [133-136]. To determine if decreased integrin expression seen in
PHLPP overexpressing cells is due to increased lysosomal degradation, we
incubated control and PHLPP overexpressing Panc-1 cells in NH4Cl containing
media. The presence of NH4Cl, a lysosomotropic alkalinizing agent, inhibits
lysosomal protein degradation. Indeed, both β4 and β1 integrin expression
increased in response to lysosome inhibition with NH4Cl (Figure 3.21). At the
end of 8-hour treatment, the expression of β4 and β1 integrin in PHLPP
overexpressing cells was similar as that of the control cells (Figure 3.21). Similar
results were obtained in cells treated with different lysosome inhibitors,
Bafilomycin A1 and chloroquine (Figure 3.21). Taken together, we showed that
inhibition of lysosome-mediated protein degradation rescues the integrin
expression in PHLPP overexpressing pancreatic cancer cells.
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Figure 3.21. Inhibiting lysosomal degradation pathway gives enhanced
expression of integrin.
(A) Stable control and PHLPP overexpressing Panc-1 cells were treated with
NH4Cl (5 mM) for 2, 4, and 8 hours. Cell lysates were prepared and analyzed by
immunoblotting for integrin expression. (B) Stable control and PHLPP
overexpressing Panc-1 cells were treated with Bafilomycin A (BA) or Chloroquine
(CQ) for 4 hours. Cell lysates were prepared and analyzed by immunoblotting for
β4 integrin expression.
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Chapter 4. Discussion and Future Directions

PHLPP functions as a negative regulator of cell migration in pancreatic
cancer.
A number of recent studies have provided strong evidence suggesting that
PHLPP serves as an important tumor suppressor in various cancer types [103,
106-108, 125, 126, 137]. For example, it has been shown that PHLPP is
downregulated in colon cancer patients and decreased PHLPP expression
promotes tumor growth as the result of increased activation of both PI3K/Akt and
RAS/RAF oncogenic signaling [103, 108, 114]. Similarly, reduced PHLPP
expression has been reported in pancreatic cancer patient specimens and reexpression of PHLPP1 in pancreatic cancer cells induces cell death and inhibits
tumorigenesis [111]. However, the role of PHLPP in regulating cell migration has
not been determined in pancreatic cancer. Here we show that PHLPP plays an
important role in influencing cell motility. Specifically, overexpression of either
PHLPP isoform decreases cell migration whereas knockdown of endogenous
PHLPPs significantly enhances cell motility in pancreatic cancer cells. The role of
PHLPP in pancreatic cancer has been supported by the results obtained from
wound healing assay, transwell assay, and single cell motility assays. Moreover,
the level of PHLPP expression regulates the ability of pancreatic cancer cells to
grow in 3D culture.

This effect can be seen in both the knockdown and

overexpressing pancreatic cells.

Knockdown PHLPP ASPC-1 cells have

significantly larger cluster formation; whereas, overexpressing PHLPP in Panc-1
cells significantly inhibits the formation of large clusters. Instead these Panc-1
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overexpressing PHLPP pancreatic cancer cells have a much reduced cluster size
compared to control as well as loss of filamentous extensions and protrusions
from the cell and cluster. This PHLPP-mediated inhibition of cell growth and
migration coincides with inhibition of both Akt and MEK/ERK activation. In our
study, the effect of PHLPP on regulating cell motility in pancreatic cancer cells is
not isoform specific, with either PHLPP1 or PHLPP2 overexpression is able to
inhibit cell migration whereas knockdown of either isoform results in a similar
increase in cell motility. This lack of isoform specificity is also seen in regarding
to the changes in EMT phenotype of pancreatic cancer cells. In Panc-1 cells
overexpressing either isoform results in enhanced expression of E-cadherin and
loss of vimentin. E-cadherin is an epithelial cell marker whereas vimentin is
considered a mesenchymal cell marker. Loss of E-cadherin and gain of vimentin
are the phenotypes associated with EMT and increased migratory potential. The
enhanced EMT phenotype is shown in stable PHLPP knockdown ASPC-1 cells
when compared to control. Pancreatic cancer is extremely aggressive and can
quickly become metastatic. It is important to find new chemotherapy targets that
are unique to pancreatic cancer. PHLPP’s ability to influence EMT and migration
of pancreatic cancer is likely related to its regulation of integrin degradation.
Reduced integrin expression at the cell membrane may impair lamellopodia
extension and adhesion to the ECM that are required for cell migration. Taken
together, our findings establish a novel link connecting PHLPP downregulation
with enhanced integration function in pancreatic cancer.
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Regulation and functional implication of integrin trafficking
In this study, we show that PHLPP plays a novel role in altering integrin
expression.

Since varying PHLPP expression, meaning overexpression of

PHLPP in Panc-1 cells or treating cells with PI3K/Akt inhibitors such as AktVIII
and LY294002, has no effect on decreasing the mRNA levels of integrins,
PHLPP may regulate integrin expression via a post-translational mechanism. Our
findings that PHLPP overexpression and treating cells with PI3K/Akt inhibitors
result in a similar decrease in β1 and β4 integrin expression suggest that reduced
Akt activity is likely the molecular mechanism underlying PHLPP-mediated
downregulation of integrins. Indeed, knockdown of either Akt1 or Akt2
significantly decreases both β1 and β4 integrin expression. Furthermore, using
lysosome inhibitors we find that the expression of both β1 and β4 integrins
increase significantly, rescuing the effects of PHLPP overexpression in Panc-1
cells. Whereas, treating cells with a proteasome inhibitor MG-132 has no effect
on rescuing β1 and β4 integrin expression in PHLPP overexpressing cells. This
gives the first hint that the point of influence for PHLPP may be in allowing for
integrin degradation instead of endosomal recycling. Another interesting finding
is that EGFR protein expression is altered in response to changes of PHLPP
expression levels to a similar extent as the integrin protein expression. When
PHLPP is overexpressed, EGFR protein expression is reduced or inhibited
compared to control; however, when PHLPP is lost through a stable knockdown
mechanism EGFR protein expression is increased. When lysosome inhibitors are
used to treat pancreatic cancer cells there is an enhanced expression of integrin
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compared to untreated cells, and lysosomal inhibitors are able to rescue the loss
of integrin expression in PHLPP overexpressing cells. These results suggest that
PHLPP may regulate integrin expression by promoting lysosomal-mediated
degradation of integrin proteins. Previous studies have supported the notion that
of lysosome plays a major role in mediating degradation of integrin [133, 134,
138, 139]. If PHLPP can enhance integrin lysosomal degradation then cell
motility may be halted therefore providing a new possible therapeutic target to
prevent metastasis of pancreatic cancer.
The cell surface delivery and endocytosis of integrins are dynamically
regulated processes and are fundamental for cell migration in wound healing and
during cancer cell metastasis [138, 140]. Like many cell surface receptors,
integrins are known to undergo endo/exocytic cycles, in which they are
internalized, trafficked through endosome, and then recycled back to the plasma
membrane [100, 139-141]. This recycle process occurs rather efficiently as the
degradation rates of integrins are generally very slow [136, 142]. However,
recent studies reveal that ligand-bound integrins can be ubiquitinated and sorted
to lysosome for degradation by the ESCRT pathway [136, 143]. Preventing
lysosome-mediated degradation of integrins increases recycling of integrins to
the plasma membrane and enhances integrin-mediated cancer cell migration and
invasion [139, 141]. It was recently discovered that sorting nexin 17 binds to the
free cytoplasmic tail of β1-integrin while in the endosome preventing its
degradation and allowing for endosomal recycling [144]. Endosomal recycling of
cell surface receptors and integrins is a major process that may confer EMT and
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aggressiveness of cancer. The ability of cancer cells to recycle receptor tyrosine
kinases (RTKs) and integrins allow them to effectively and efficiently produce
extensions that allow for migration [138]. It has been suggested that oncogenic
mutations in EGFR may allow for the receptors to evade lysosomal degradation
and promote tumor progression [138].

Accepted beliefs in EGFR signaling

include that the majority of signaling occurred at the plasma membrane and is
attenuated through endosomal internalization of the receptor. However, this was
recently challenged when it was demonstrated that signaling can still occur after
internalization from the actual endosomes [145]. Oncogenic mutations in EGFR
lead to sustained activation even when there is a large deletion of the
extracellular domain. This gives a constitutively active protein with less ability to
be silenced through internalization [145]. It is a possibility that when EGFR and
integrin reside in the same lipid raft that these types of mutations in EGFR could
lead to reduction of internalization of integrin and allowing for sustained signaling
through integrin itself by keeping it in the active conformation [146]. In addition,
there is evidence supporting a physical interaction between EGFR and integrins,
which would provide another mechanism for coordinated control of EGFR and
integrin protein expression [147].
Promotion of lysosome-dependent degradation of integrins, has been
shown previously, by activating PI3K/Akt signaling which enhances integrin
recycling to the plasma membrane in a GSK-3β-dependent manner. GSK-3β
phosphorylates kinesin light chain and inhibits the activity of kinesin. This leads
to inhibition of endosomes trafficking through the microtubules and subsequent
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maturation into late endosomes and merging with the lysosomes [148]. One
assay that could be performed to determine the potential involvement of GSK-3β
is to determine the phosphorylation of GSK-3β in PHLPP overexpressing Panc-1
cells and PHLPP knockdown ASPC-1 cells. It has been shown recently that
GSK-3β and Akt are associated with Appl endosomes, a subpopulation of early
endosomes [149]. It is possible that the close association of Akt and GSK-3β
allows for Akt-mediated phosphorylation and subsequently inactivation of GSK3β. In pancreatic cancer, activation of Akt as the result of PHLPP-loss would lead
to inactivation of GSK-3β and allow integrins to bypass lysosomal-mediated
degradation and remain membrane bound. Using integrin recycling assays, we
would be able to look at integrin recycling under various settings, such as PHLPP
overexpressing cells, PHLPP knockdown cells, Akt knockdown cells, activation of
the PI3K/Akt pathway via stimulation with growth factor receptor ligands, and
inhibition of the PI3K/Akt pathway using inhibitors. This assay will allow us to
directly assess how integrin expression at the plasma membrane is regulated by
PHLPP and PI3K/Akt signaling.
At this moment our data suggests the involvement of PI3K/Akt pathway on
regulating integrin expression, but our data is limited to using the inhibitor
approach. Since the pancreatic cancer cells used in our study contain a genetic
background of activated mutant KRas which allows for sustained and prolonged
activation of both the PI3K/Akt pathway and the Raf/MEK/ERK pathway, it is a
possibility of using dominant negative proteins downstream of KRas that would
provide a mechanism to tease out the role that each pathway plays. We are able

115

to silence Akt and we can use shRNA to knockdown function of Raf/MEK/ERK or
we can overexpress a dominant negative form of Raf1 which would help in
terminating the Raf/MEK/ERK signaling pathway [150]. A dominant negative form
of ERK could also be used to create a situation where the pathway is terminated
further down the cell signaling cascade.

This was investigated in human

pancreatic cancer cell lines and it was discovered that expression of dominant
negative ERK lead to reduced survival of pancreatic cancer cells in colony
formation studies [151]. Using these approaches we could further elucidate either
the PI3K/Akt pathway or the Raf/MEK/ERK pathway is responsible for altering
integrin protein expression. These additional studies are needed in order to
provide a complete picture for future therapeutic targets.
Another role Akt may play in integrin expression is through direct
phosphorylation. It has been shown that Akt phosphorylates both β3 and β1
integrins tail thereby allowing adhesion molecules to interact with their tails
keeping them forcefully anchored within the cell membrane [152, 153]. It is
interesting that β4 integrin carries the longest tail out of all of the integrins and
would allow for direct Akt phosphorylation. Future experiments can be performed
to replace endogenous β4 integrin with a mutant β4 integrin that lacks the
cytoplasmic tail. Comparing the effect of PHLPP on regulating the expression of
mutant integrin with the wild-type integrin will allow for further elucidation of the
molecular mechanism by which PHLPP controls the expression of integrins.
Using TIRF microscopy as shown in Figure 3.11-3.12 we can determine if
mutant β4 and β1 integrin are better retained at the basolateral membrane. As in
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Figure 3.12 the staining of integrin is punctate and may coincide with recycling
endosomes. This can also be viewed through TIRF imaging by looking at colocalization of integrin with recycling endosomal marker Rab11 [154]. There is
evidence suggesting that PHLPP is associated with the plasma membrane or the
endosomal membrane [126, 155]. Using TIRF we could demonstrate the
possibility of a physical interaction between PHLPP and integrin at the plasma
membrane or the endosomal level. PHLPP has a PH domain that has been
shown to bind PIP3.

PIP3 is also found on endosomes therefore providing

another possible link between PHLPP and integrin [156].
In a previous study an ARF GAP called ACAP1 was shown to be targeted
to recycling endosomes in order to sort cargo leading either to lysosomal
degradation or allowed to recycle to the plasma membrane.

Li et al

demonstrated that ACAP1 is required for integrin endosomal recycling and colocalizes at recycling endosomes. When cells are stimulated, most likely this
would be when integrin binds to its respective ligand or there’s stimulation
through an RTK, integrins (such as β1 integrin) are sent to be recycled through
recycling endosomes. ACAP1 associates with β1 integrin at the recycling
endosomes interface. Akt associates with ACAP1 and phosphorylates its Ser554
residue. This allows ACAP1 to sort the internalized endosomes cargo such as
integrin into recycling endosomes so it can be re-associated with the plasma
membrane [157]. This provides another mechanism linking Akt activation to
integrin recycling. It is possible that when PHLPP is downregulated, activated Akt
leads to phosphorylation of ACAP1 which allows the internalized integrins to be
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sorted into the recycling endosome instead of continuing its degradation path to
the lysosome. Future studies can determine the phosphorylation of ACAP in
PHLPP overexpressing and knockdown cells. In addition, ACAP1 can be
silenced using RNAi in PHLPP knockdown where Akt is continuously active to
evaluate its involvement. Co-localization of ACAP1, Akt, and integrin in
pancreatic cancer cells with the endosomal recycling marker Rab11 can also be
performed. These studies will provide additional mechanistic insight into integrin
recycling.
This PHLPP-mediated regulation of integrin recycling process likely has a
broader implication in the trafficking of membrane receptors. One interesting
observation in our study is that not only is integrin expression changed in
response to PHLPP expression, but also is EGFR a known RTK that is degraded
through the lysosomal pathway. It would not be surprising if EGFR and integrin
as well as other growth factor receptors and adhesion molecules use some of the
same mechanisms in order to regulate their lysosomal degradation and
endosomal recycling pathways. Using some of the same machinery would be
efficient and provide a unique way to regulate very intricate multi-step processes.
Thus, PHLPP represents a novel regulator of cell motility by possibly controlling
the balance of integrin recycling and degradation, as well as other RTKs, in
pancreatic cancer cells.
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Integrin and invadosomes
Integrins are believed to be found in the “invadosomes” when it comes to
migration or adhesion signaling especially in cancer [158]. Invadosomes are
structures in invasive cells that are similar to podosomes in structure and
function. It has been known for some time that integrins have two different
conformations, low and high affinity conformations, which may allow them to
sense the outside environment or particular ECM [159]. Essentially the
interaction between integrin and ECM proteins connects the motility of the cell to
the environment both internal and external [158]. Although a number of studies
have indicated β3 integrin as the major regulator of invadosome formation
because of its co-localization with the invadosome structures [160, 161], β3
integrin deficient cells are still capable of forming invadosomes [162]. Additional
studies show that β1 but not β3 integrins are required for invadosome formation
and stabilization; and the activation state of β1 has been linked to the integrinmediated degradation of ECM [162, 163]. It has been suggested that actin
bundles are grouped together with integrins and the ECM substrates to create
the invadosomes (Figure 4.1) [162].
There are some novel concepts that allow for these invadosomes to
become predominantly explored in the future of cancer and especially pancreatic
cancer research. One such interesting concept is that metallomatrix proteins are
used by the invadosomes to promote degradation of the ECM to allow for the
invadopodia and invadosome formation in cancer cells [164]. In addition, it has
been shown not only pancreatic cancer cells but the cancer-associated
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fibroblasts (CAFs) can form invadosomes as well. One study demonstrates that
high expression of palladin in CAFs promotes the formation of invadosomes and
invadopodia, which are responsible for creating channels in the ECM for
pancreatic cancer cells to invade and metastasize through tumor stroma [165].
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Figure 4.1. The invadosome and its components.
The invadosome is comprised of many components with the major players being
integrins, receptors, the lipid membrane, actin, talin, and other proteins and
structures of the cell. This figure is adapted from Albiges-Rizo et al. [166].
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Interestingly, Neel et al. have discovered that KRAS mutation by itself was
sufficient to induce invadopodia formation in pancreatic cancer cells. However,
activation of the RAF/MEK/ERK pathway is not required to form the invadopodia
whereas treating cells with inhibitors of the PI3K/Akt pathway blocks the
formation of invadopodia [167]. This finding supports our results that PHLPPdependent downregulation of integrin expression is mediated by Akt inactivation
and inhibition of the PI3K/Akt pathway in pancreatic cancer cells. Enhanced
activation of Akt in PHLPP knockdown cells may sustain the expression of
integrin via continual recycling of integrins to the membrane. Given the role of
integrin in promoting invadosome formation, loss of PHLPP may enhance the
invasive growth of pancreatic cancer cells through invadosomes and invadopodia
formation. To support this hypothesis, we find that the expression of integrin is
mainly localized at the cell extensions in PHLPP knockdown ASPC-1 cells as
detected by TIRF microscopy (Figure 3.11-3.12).

The vesicle-like staining

patterns of integrins may reflect the recycling of integrins that are associated with
invadosome through the endosomes along the actin bundles. Future studies are
needed to further test the hypothesis that Akt activity is involved in regulating the
trafficking and recycling of integrins and to elucidate how integrins are
internalized from the invadosomes through the endocytic pathway and sorted for
lysosomal degradation.
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Conclusions
While our study provides the first glimpse of PHLPP as a tumor
suppressor in pancreatic cancer as a regulator of migration through possible
control of integrin expression and degradation, more studies are needed to
extend our findings. To determine the functional significance of PHLPP in vivo,
we can take advantage of PHLPP1 and PHLPP2 knockout mice. It will be
important to investigate if PHLPP-loss promotes pancreatic carcinoma formation
and progression in vivo using mouse models. Future studies can be performed to
cross PHLPP1 or PHLPP2 knockout mice with KRas activating mutant mice in
order to develop a working mouse model where the effect of PHLPP-loss in
pancreatic will be monitored on the background of KRas activation. Since only
KRAS mutation is needed to begin the process of PanIN development, it is
feasible that elimination of tumor suppressor PHLPP would accelerate pancreatic
tumorigenesis in these mouse models. Additional studies on signaling activation
as the result of PHLPP-loss will help to identify potential therapeutic targets in
pancreatic cancer.
As previously stated, late stage diagnosis and the aggressiveness of
pancreatic carcinoma, PDAC patients have a very low survival rate [124, 168].
The treatment options for PDAC are few and surgical resection is nearly
impossible for the average patient [169]. Understanding the molecular
mechanism leading to EMT and progression of PDAC potentially has a long
lasting benefit in creating new treatment strategies, therapeutic targets, and even
gene editing techniques. In this study, we provide the first strong evidence
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supporting a tumor suppressor role of PHLPP in pancreatic cancer. Moreover,
our finding that decreased PHLPP expression promotes EMT and cell motility
through the possibility of inhibiting lysosome degradation of integrin proteins
identifies a novel mechanism by which PHLPP suppresses oncogenic signaling.
Further studies are warranted to further elucidate how PHLPP controls the
protein expression of integrin through Akt activity. The ramifications of future
studies would not only benefit pancreatic cancer but possibly contribute to
carcinoma knowledge across all cancer types as well as auto-immune disorders,
aging related diseases, diabetes, obesity, and other PI3K/Akt and Raf/MEK/ERK
pathway related diseases. Taken together, our study highlights the importance
of future studies to further explore the possibility of using PHLPP as a diagnostic
marker and a chemotherapeutic target in pancreatic cancer.
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Appendix
List of Abbreviations
BA: Bafilomycin A
CAF: Cancer-associated fibroblast
CQ: Chloroquine
DHH: Desert hedgehog
ECM: Extracellular matrix
EGFR: Epidermal growth factor receptor
EMT: Epithelial-mesenchymal transition
FBS: Fetal bovine serum
GSK-3β Glycogen synthease kinase 3β
HGF: Hepatocyte growth factor
Hh: Hedgehog
IF: Immunofluorescence
IGF-1: Insulin-like growth factor 1
IHH: Indian hedgehog
IRS: Insulin receptor substrate
MET: Mesenchymal-epithelial transition
PanIN: Pancreatic intraepithelial neoplasia
PDAC: Pancreatic ductal adenocarcinoma
PEI: Polyethylenimine
PHLPP: PH domain leucine-rich-repeats protein phosphatase
PI3K: Phosphatidylinositol-3-kinases
PKC: Protein kinase C
PTC: Patched
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qRT-PCR: Quantitative real-time PCR
RTK: Receptor tyrosine kinase
SCOP: Suprachiasmatic nucleus oscillatory protein
SHH: Sonic hedgehog
SMO: Smoothened
TGF-β: Transforming growth factor β
TIRF: Total internal reflection fluorescence
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IL-17 module design and editing
Medical review of content
Pfizer Drug Representative Module for Treatment of Menopausal Symptoms,
(May 2014)
Editing medical and scientific content
Validating references

Awards & Honors
2012 ASCB Grant Conference Funding
2012 ASBMB Child Care Grant
Member of Phi Beta Kappa: joined during undergraduate
Member of Scientists and Engineers of America
Dean’s List: Salem International University & University of Arkansas at Little
Rock
Conferences
NASA_EPSCORE 2009 conference, Arkansas
NASA_EPSCORE 2010 Conference, Arkansas
ASBMB Conference 2012, San Diego, CA. “Loss of PHLPP Expression in
Pancreatic Cancer”
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ASCB Conference Chair 2012 Appalachian Biology Conferences,
Charleston, WV
AACR 1013 Attendee
ASCB Conference Chair/Director October 2013, Appalachian Biology
Conference, Charleston, WV
AACR Pancreatic Cancer Conference April 2014, New Orleans, Louisiana

GRANTS
ASCB Conference Funding Request Appalachian Regional Cell Conference
2012
Funded
ASCB Conference Funding Request Appalachian Regional Cell Conference
2013
Funded
ASCB Conference Funding Request Appalachian Regional Cell Conference
2014
Funded

Positions Held
CEO LenaJeanne Cosmetics (2013-present)
Board of Directors (2011- present)
Appalachian Regional Cell Conference

Manuscripts in Revision
"PHLPP negatively regulates cell motility through inhibition of Akt activity
and integrin expression in pancreatic cancer cells"
References will be given upon request.
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